ArticleFrontiers in cardiovascular medicine2025
Case Report: Practice of whole-course pharmaceutical care: a case in hypertrophic cardiomyopathy and a review of the pharmacist's role.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Agent-specific bleeding signatures in non-hypertensive versus hypertensive patients exposed to oral anticoagulants: a real-world pharmacovigilance study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Signal detection of drug-induced esophageal ulcer across 20 years of real-world study: Focus on 49 high-risk medicines.The Journal of international medical research · 2026Article
- A real-world pharmacovigilance analysis of cardiac, endocrine, and neurological adverse events associated with cabergoline: a disproportionality study.Archives of medical science : AMS · 2026Article
- Effect of a WeChat-based medication reminder platform onFrontiers in medicine · 2026Article
- Antithrombotic management in an elderly CABG patient with nephrotic syndrome: a case report.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical pharmacists supported clinicians in medication planning and health education for a male patient diagnosed with hypertrophic cardiomyopathy (HCM). Therapeutically, diltiazem was replaced with metoprolol to further alleviate symptoms. Whole-blood exon sequencing revealed a pathogenic mutation in the beta-myosin heavy chain gene (MYH7, OMIM #160760), consistent with dominant inheritance. Furthermore, low-intensity exercise and screening of the patient's children were recommended. In addition, we provided an overview of current therapeutic approaches, emphasizing potential novel agents and non-pharmaceutical interventions for HCM management. This is the first case report to highlight not only updates in HCM treatment but also the pharmacist's role in long-term HCM management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.